BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Frampton JE. Rotigotine Transdermal Patch: A Review in Parkinson’s Disease. CNS Drugs 2019;33:707-18. [DOI: 10.1007/s40263-019-00646-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Chopade P, Chopade N, Zhao Z, Mitragotri S, Liao R, Chandran Suja V. Alzheimer's and Parkinson's disease therapies in the clinic. Bioengineering & Transla Med. [DOI: 10.1002/btm2.10367] [Reference Citation Analysis]
2 Ferraiolo M, Atik H, Ponthot R, Koener B, Hanson J, Hermans E. Dopamine D2L receptor density influences the recruitment of β-arrestin2 and Gi1 induced by antiparkinsonian drugs. Neuropharmacology 2022;207:108942. [PMID: 35026287 DOI: 10.1016/j.neuropharm.2022.108942] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Yan J, Ma H, Liu A, Huang J, Wu J, Yang J. Efficacy and Safety of Rotigotine Transdermal Patch on Neuropsychiatric Symptoms of Parkinson's Disease: An Updated Meta-Analysis and Systematic Review. Front Neurol 2021;12:722892. [PMID: 34744967 DOI: 10.3389/fneur.2021.722892] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Ibrahim H, Woodward Z, Pooley J, Richfield EW. Rotigotine patch prescription in inpatients with Parkinson's disease: evaluating prescription accuracy, delirium and end-of-life use. Age Ageing 2021;50:1397-401. [PMID: 33264385 DOI: 10.1093/ageing/afaa256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Woodruff BC, Garcia D, Chaudhari S. Preoperative Evaluation of Parkinson's Disease. Cureus 2021;13:e15933. [PMID: 34336434 DOI: 10.7759/cureus.15933] [Reference Citation Analysis]
6 Silva S, Almeida AJ, Vale N. Importance of Nanoparticles for the Delivery of Antiparkinsonian Drugs. Pharmaceutics 2021;13:508. [PMID: 33917696 DOI: 10.3390/pharmaceutics13040508] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
7 Raeder V, Boura I, Leta V, Jenner P, Reichmann H, Trenkwalder C, Klingelhoefer L, Chaudhuri KR. Rotigotine Transdermal Patch for Motor and Non-motor Parkinson's Disease: A Review of 12 Years' Clinical Experience. CNS Drugs 2021;35:215-31. [PMID: 33559846 DOI: 10.1007/s40263-020-00788-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Yasutaka Y, Fujioka S, Mishima T, Shibaguchi H, Tsuboi Y, Kamimura H. How to introduce a rotigotine patch to Parkinson's disease patients taking oral dopamine agonists. Clin Neurol Neurosurg 2020;199:106266. [PMID: 33059317 DOI: 10.1016/j.clineuro.2020.106266] [Reference Citation Analysis]
9 Hou L, Zhang L, Hong J, Zhang D, Zhao J, Wang Q. Nicotinamide Adenine Dinucleotide Phosphate Oxidase and Neurodegenerative Diseases: Mechanisms and Therapy. Antioxidants & Redox Signaling 2020;33:374-93. [DOI: 10.1089/ars.2019.8014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
10 Md S, Karim S, Saker SR, Gie OA, Hooi LC, Yee PH, Kang AWC, Zhe CK, Ian N, Aldawsari HM, Hosny KM, Alhakamy NA. Current Status and Challenges in Rotigotine Delivery. Curr Pharm Des 2020;26:2222-32. [PMID: 32175832 DOI: 10.2174/1381612826666200316154300] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]